Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Q-Med AB

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Q-Med AB

Regulatory records
16
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 16 FDA records to the applicant name Q-Med AB. It includes 2 original PMA approvals. 7 entries are PMA supplements. 7 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 3, 2004 to Sep 18, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LMH appears in 16 of the 16 linked filings. The collection spans 1 FDA product code and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P040024, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: Seminariegatan 21, Uppsala, S-752 28. Recorded on P140029/S058, decision dated Sep 18, 2026.

Changes described in PMA records

P140029/S058: Restylane Contour

FDA’s recorded scope: approval for updated device labeling, including the addition of a statement regarding how the Restylane Contour is only for distribution to providers that have taken and successfully completed device-specific use training program when used for the correction of temple hollowing in patients over the age of 21.

Sep 18, 2026 · Normal 180 Day Track No User Fee

P030050/S056: SCULPTRA (injectable poly-L Lactic acid)

The FDA record for P030050/S056 lists a 30-day notice with decision OK30, dated 2026-09-17, for SCULPTRA (injectable poly-L lactic acid). The stated purpose is to modify compounding reactors R11 and R12 so they are consistent with reactor systems R11A and R12A. The supplement reason is given as a process change covering manufacturer, sterilizer, packager or supplier.

The filing does not describe how the reactors were changed, how R11A and R12A differ from R11 and R12, or what consistency means in engineering terms, so those details remain unknown. The stated purpose is a manufacturing change; it is not reported evidence of safety or clinical effectiveness. The identifier P030050 links the notice to the original PMA for this device, but a supplement is not an approval of the whole system.

FDA approval-order wording

Approval to modify compounding reactors R11 and R12 to be consistent with reactor systems R11A and R12A.

Sep 17, 2026 · 30-Day Notice

P140029/S057: Restylane Contour

FDA’s recorded scope: Approval for the post-approval study protocol to evaluate the safety of re-treatment with Restylane Contour in the treatment of temple hollowing

May 15, 2026 · Normal 180 Day Track No User Fee

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

  1. Restylane Contour

    P140029/S058 · PMA supplement
  2. SCULPTRA (injectable poly-L Lactic acid)

    P030050/S056 · PMA supplement
  3. SCULPTRA (injectable poly-L Lactic acid)

    P030050/S055 · PMA supplement
  4. Restylane Contour

    P140029/S057 · PMA supplement
  5. SCULPTRA AND SCULPTRA AESTHETIC

    P030050/S054 · PMA supplement
  6. Restylane Refyne, Restylane Defyne, Restylane Kysse and Restylane Contour

    P140029/S056 · PMA supplement
  7. Restylane Contour

    P140029/S054 · PMA supplement
  8. RESTYLANE INJECTABLE GEL

    P040024/S148 · PMA supplement
  9. Restylane Lyft with Lidocaine

    P040024/S147 · PMA supplement
  10. Restylane-L 1 mL; Restylane Lyft with Lidocaine 1 mL; Restylane Eyelight 0.5 mL

    P040024/S143 · PMA supplement
  11. Restylane Lyft with Lidocaine

    P040024/S146 · PMA supplement
  12. Restylane Lyft with Lidocaine

    P040024/S142 · PMA supplement
  13. Restylane Refyne, Restylane Defyne, Restylane Kysse and Restylane Contour

    P140029/S055 · PMA supplement
  14. Restylane Injectable Gel

    P040024/S144 · PMA supplement
  15. Restylane Refyne, Restylane Defyne

    P140029 · PMA decision
  16. SCULPTRA AND SCULPTRA AESTHETIC

    P030050 · PMA decision
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.